The team at INEX Innovate is proud to announce the attainment of CE marking for it’s 𝐎𝐯𝐚𝐂𝐢𝐬® 𝐑𝐚𝐩𝐢𝐝 𝐓𝐞𝐬𝐭 as covered by industry publication BioSpace.
Slated to launch in the EU and Southeast Asian markets by the end of 2022, 𝐎𝐯𝐚𝐂𝐢𝐬® is a first of its kind point-of-care (POCT) test that discriminates benign from malignant ovarian cysts screens ovarian cysts for malignancy in an operating theatre setting.
𝐎𝐯𝐚𝐂𝐢𝐬® 𝐑𝐚𝐩𝐢𝐝 𝐓𝐞𝐬𝐭 empowers surgeons to make fast informed evidence-based decisions within the confines of a high pressure surgical environment by identifying a protein biomarker (haptoglobin) evenly distributed in ovarian cysts fluid to determine if the cysts are benign or malignant, providing results in 15 minutes – significantly reducing surgical procedure time.
